The inhibition of allergen induced bronchospasm in man by oral BRL 10833
- 1 September 1976
- journal article
- research article
- Published by Wiley in Clinical and Experimental Allergy
- Vol. 6 (5) , 471-478
- https://doi.org/10.1111/j.1365-2222.1976.tb01931.x
Abstract
Summary: BRL 10833, a nitroindanedione, with DSCG like activity in rat immediate type hypersensitivity, shows good absorption after oral intake in man. The ingestion of 2 and 10 mg BRL 10833/kg body weight provides protection against the immediate type allergen induced bronchoconstriction in patients with bronchial asthma.These results confirm the activity of the drug already shown by inhalation.This publication has 9 references indexed in Scilit:
- The protective effect of inhaled BRL 10833 on allergen induced bronchospasmClinical and Experimental Allergy, 1976
- DOXANTRAZOLE, AN ANTIALLERGIC AGENT ORALLY EFFECTIVE IN MANThe Lancet, 1975
- Inhibition of Experimental Asthma in Man by a New Drug (AH 7725) Active when Given by MouthBMJ, 1974
- Sodium Cromoglycate (Cromolyn Sodium)Drugs, 1974
- Double Blind Crossover Study of Cromolyn Sodium Inhibition of Aerosol Antigen ChallengeChest, 1972
- Protection tests on bronchial allergen challenge with disodium cromoglycate and thiazinamiumJournal of Allergy, 1970
- Nature and Modes of Action of Disodium Cromoglycate (Lomudal®)Respiration, 1970
- INHIBITORY EFFECTS OF DISODIUM CROMOGLYCATE ON ALLERGEN-INHALATION TESTSThe Lancet, 1968
- Disodium Cromoglycate (FPL 670) (‘Intal’*): a Specific Inhibitor of Reaginic Antibody–Antigen MechanismsNature, 1967